Patients with lung cancer reduce smoking rate after enrollment in phase III clinical trial
Subset of COVID-19 patients have increased bleeding risk
1 February 2021Common HIV drugs may prevent leading cause of vision loss, study finds
1 February 2021Patients with lung cancer reduce smoking rate after enrollment in phase III clinical trial
The first comprehensive, prospective study of smoking habits in patients with non-small cell lung cancer (NSCLC) who were enrolled in a phase III early-stage trial revealed that there was a high rate of smoking reduction and cessation following study entry, according to research published today in the Journal of Thoracic Oncology.
